How many drugs treat Acne vulgaris?

Drug Landscape tracks 10 marketed treatments for Acne vulgaris (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Acne vulgaris?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acne-vulgaris.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acne vulgaris — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acne vulgaris (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acne vulgaris, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Winlevi	CLASCOTERONE	Sun Pharma	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Differin	ADAPALENE	Galderma Labs Lp	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01
Azelex	AZELAIC ACID	Leo Pharma As	azelaic acid	3-oxo-5-alpha-steroid 4-dehydrogenase 2	1995-01-01
Iron Fumarate	FERROUS FUMARATE	Pfizer	Vitamin C [EPC]		1986-01-01
Benzamycin	BENZOYL PEROXIDE	Mayne Pharma	benzoyl peroxide		1984-01-01
Aczone	DAPSONE	Almirall	Sulfone [EPC]	5-hydroxytryptamine receptor 6	1979-01-01
Estron	ESTRONE	Watson Labs	estrone	Estrogen receptor	1979-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Aygestin	NORETHINDRONE ACETATE	Duramed Res	Estrogen [EPC]	Progesterone receptor	1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US
2026-03-25 — Retin-A · FDA · approved · US
2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Acne vulgaris
Pfizer · 5 drugs in Acne vulgaris
Merck & Co. · 2 drugs in Acne vulgaris
Aier School of Ophthalmology, Central South University · 1 drug in Acne vulgaris
Bausch Health · 1 drug in Acne vulgaris
Bulovka Hospital · 1 drug in Acne vulgaris
Astellas Pharma · 1 drug in Acne vulgaris
Exeltis Usa Inc · 1 drug in Acne vulgaris
Galderma Labs Lp · 1 drug in Acne vulgaris
Generic (originally Abbott/Lilly) · 1 drug in Acne vulgaris
Generic (originally Merck/Upjohn) · 1 drug in Acne vulgaris
Duramed Res · 1 drug in Acne vulgaris

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acne vulgaris:

Cite this brief

Drug Landscape (2026). Acne vulgaris — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acne-vulgaris. Accessed 2026-06-10.

Acne vulgaris full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing